Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Receivables - Net: 2013-2025

Historic Receivables - Net for CorMedix (CRMD) over the last 9 years, with Sep 2025 value amounting to $158.6 million.

  • CorMedix's Receivables - Net rose 812.00% to $158.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.6 million, marking a year-over-year increase of 812.00%. This contributed to the annual value of $51.7 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, CorMedix's Receivables - Net stood at $158.6 million, which was up 269.54% from $42.9 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Receivables - Net registered a high of $158.6 million during Q3 2025, and its lowest value of $2,975 during Q1 2022.
  • For the 2-year period, CorMedix's Receivables - Net averaged around $54.2 million, with its median value being $47.3 million (2024).
  • Per our database at Business Quant, CorMedix's Receivables - Net tumbled by 93.18% in 2022 and then surged by 20,696.87% in 2025.
  • Quarterly analysis of 4 years shows CorMedix's Receivables - Net stood at $45,368 in 2021, then tumbled by 93.18% to $2,975 in 2022, then reached $51.7 million in 2024, then surged by 812.00% to $158.6 million in 2025.
  • Its Receivables - Net was $158.6 million in Q3 2025, compared to $42.9 million in Q2 2025 and $54.6 million in Q1 2025.